A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

June 23, 2005 updated by: Pharmacia and Upjohn
To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate (U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Puerto Rico
      • San Juan, Puerto Rico, 00936
        • UPR School of Medicine
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 352942041
        • Univ of Alabama at Birmingham
    • California
      • Berkeley, California, United States, 94705
        • East Bay AIDS Ctr
      • Fresno, California, United States, 93726
        • California Med Research Group
      • Los Angeles, California, United States, 90095
        • CARE Ctr / UCLA Med Ctr
      • Los Angeles, California, United States, 900331079
        • Los Angeles County - USC Med Ctr
      • Los Angeles, California, United States, 90059
        • Los Angeles County / Health Research Assoc / Drew Med Ctr
      • Orange, California, United States, 92668
        • UCI Med Ctr
      • Redwood City, California, United States, 94063
        • AIDS Community Research Consortium
      • Sacramento, California, United States, 95817
        • UCD Med Ctr / AIDS and Related Disorders Clinic
      • San Diego, California, United States, 92101
        • St Lukes Medical Group
      • San Diego, California, United States, 92103
        • UCSD / Ctr for Special Immunology
      • San Francisco, California, United States, 94114
        • Davies Med Ctr
      • San Francisco, California, United States, 94103
        • ViRx Inc
      • San Francisco, California, United States, 94109
        • Saint Francis Mem Hosp
      • Tarzana, California, United States, 91356
        • Shared Med Research Foundation
      • Torrance, California, United States, 90509
        • Harbor - UCLA Med Ctr
    • Colorado
      • Denver, Colorado, United States, 80262
        • Univ Hosp / Univ of Colorado Health Sci Ctr
    • District of Columbia
      • Washington, District of Columbia, United States, 20037
        • George Washington Univ Med Ctr
      • Washington, District of Columbia, United States, 20007
        • Georgetown Univ Med Ctr
    • Florida
      • Miami, Florida, United States, 33136
        • Univ of Miami School of Medicine
      • Palm Beach Gardens, Florida, United States, 33410
        • Caremark Inc
      • Tampa, Florida, United States, 33614
        • Infectious Disease Research Institute Inc
    • Georgia
      • Atlanta, Georgia, United States, 30345
        • Infectious Disease Rsch Consortium of GA / SE Clin Resources
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Rush Presbyterian - Saint Luke's Med Ctr
      • Chicago, Illinois, United States, 60612
        • Univ of Illinois
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana Univ Infectious Disease Research Clinic
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • Univ of Iowa
    • Kansas
      • Kansas City, Kansas, United States, 661607354
        • Univ of Kansas School of Medicine / Univ Hosp
      • Wichita, Kansas, United States, 67214
        • Univ of Kansas School of Medicine
    • Kentucky
      • Lexington, Kentucky, United States, 405360084
        • Univ of Kentucky Med Ctr / Chandler Med Ctr
    • Louisiana
      • New Orleans, Louisiana, United States, 701122699
        • Tulane Univ Med School
    • Maine
      • Portland, Maine, United States, 04102
        • AIDS Consultation Service / Maine Med Ctr
    • Maryland
      • Baltimore, Maryland, United States, 21201
        • Univ of Maryland at Baltimore
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Brigham and Women's Hosp
      • Boston, Massachusetts, United States, 02215
        • New England Deaconess Hosp
      • Boston, Massachusetts, United States, 02114
        • Massachusetts Gen Hosp
      • Boston, Massachusetts, United States, 02118
        • Boston City Hosp / FGH-1
      • Springfield, Massachusetts, United States, 01199
        • Baystate Med Ctr of Springfield
      • Worcester, Massachusetts, United States, 01655
        • Univ of Massachusetts Med Ctr
    • Michigan
      • Ann Arbor, Michigan, United States, 481090378
        • Univ of Michigan Hospitals and Health Ctrs
      • Detroit, Michigan, United States, 48202
        • Henry Ford Hosp
      • Detroit, Michigan, United States, 48201
        • Harper Hosp
    • Minnesota
      • St. Paul, Minnesota, United States, 55101
        • St Paul Ramsey Med Ctr / HIV Program Office
    • Missouri
      • Kansas City, Missouri, United States, 64108
        • Univ of Missouri at Kansas City School of Medicine
      • St. Louis, Missouri, United States, 63110
        • Washington Univ
    • Nebraska
      • Omaha, Nebraska, United States, 681985130
        • Univ of Nebraska Med Ctr / HIV Clinic
    • New Jersey
      • Neptune, New Jersey, United States, 07753
        • Jersey Shore Med Ctr
    • New York
      • Albany, New York, United States, 122083479
        • Albany Med College
      • Buffalo, New York, United States, 14215
        • SUNY / Erie County Med Ctr at Buffalo
      • New York, New York, United States, 10003
        • Beth Israel Med Ctr
      • New York, New York, United States, 10029
        • Mount Sinai Med Ctr
      • New York, New York, United States, 10001
        • Community Research Initiative on AIDS
      • New York, New York, United States, 10021
        • New York Hosp - Cornell Med Ctr
      • New York, New York, United States, 10011
        • Saint Vincent's Hosp and Med Ctr
      • Rochester, New York, United States, 14642
        • Univ of Rochester Med Ctr
      • Rochester, New York, United States, 14620
        • Community Health Network
      • Stony Brook, New York, United States, 117948153
        • SUNY / Health Sciences Ctr at Stony Brook
      • Valhalla, New York, United States, 10595
        • New York Med College / Westchester County Med Ctr
    • North Carolina
      • Chapel Hill, North Carolina, United States, 275997215
        • Univ of North Carolina School of Medicine
      • Charlotte, North Carolina, United States, 28204
        • Carolinas Med Ctr
      • Durham, North Carolina, United States, 27710
        • Duke Univ Med Ctr
    • Ohio
      • Cincinnati, Ohio, United States, 45267
        • Univ of Cincinnati / Holmes Hosp
    • Oregon
      • Portland, Oregon, United States, 97210
        • Portland Veterans Adm Med Ctr / Rsch & Education Grp
    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • Pennsylvania State Univ / Hershey Med Ctr
      • Philadelphia, Pennsylvania, United States, 19107
        • Buckley Braffman Stern Med Associates
      • Philadelphia, Pennsylvania, United States, 19104
        • Univ of Pennsylvania / HIV Clinic
      • Philadelphia, Pennsylvania, United States, 19146
        • Oncology and Hematology Association
      • Philadelphia, Pennsylvania, United States, 19104
        • Children's Hosp of Philadelphia
      • Pittsburgh, Pennsylvania, United States, 15261
        • Univ of Pittsburgh Med School
    • Rhode Island
      • Pawtucket, Rhode Island, United States, 02860
        • Mem Hosp of Rhode Island
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Med Univ of South Carolina
    • Tennessee
      • Memphis, Tennessee, United States, 38163
        • Univ of Tennessee
      • Nashville, Tennessee, United States, 37212
        • Vanderbilt Univ
    • Texas
      • Austin, Texas, United States, 78751
        • Central Texas Med Foundation
      • Dallas, Texas, United States, 75216
        • Dallas Veterans Administration Med Ctr
      • Houston, Texas, United States, 77030
        • Houston Veterans Administration Med Ctr
      • Houston, Texas, United States, 77004
        • Park Plaza Hosp
      • Houston, Texas, United States, 77030
        • Univ TX Health Science Ctr
      • San Antonio, Texas, United States, 78284
        • Univ TX San Antonio Health Science Ctr
    • Vermont
      • Burlington, Vermont, United States, 05401
        • Med Ctr of Vermont Hosp
    • Virginia
      • Richmond, Virginia, United States, 23219
        • Richmond AIDS Consortium
    • Washington
      • Seattle, Washington, United States, 98104
        • Univ of Washington
    • Wisconsin
      • Madison, Wisconsin, United States, 53792
        • Univ of Wisconsin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

Concurrent Medication:

Allowed:

  • AZT.

Patients must have:

  • HIV-1 seropositivity.
  • CD4 count <= 300 cells/mm3.
  • No active or acute (onset within the past month) opportunistic infections such as active cryptococcosis, pneumocystis carinii, herpes zoster, histoplasmosis, or cytomegalovirus (CMV).
  • Consent of parent or guardian if less than 18 years of age.
  • Understanding of potential risk to fetus related to study participation.
  • Acceptable medical history, physical exam, EKG, and chest x-ray during screening.

NOTE:

  • Patients with cutaneous Kaposi's sarcoma requiring no systemic therapy are permitted.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Active tuberculosis that is sensitive to rifampin.
  • Inability to swallow numerous tablets.
  • Clinically significant active or acute medical problems, including progressive multifocal leukoencephalopathy, lymphoma, or malignancy requiring systemic therapy.
  • Clinically significant hypersensitivity to piperazine-type drugs (e.g., Antepar and Stelazine).
  • Grade 2 or worse baseline organ function. NOTE:
  • Hemophiliacs with grade 2 bilirubin, alkaline phosphatase, SGOT, or SGPT will be considered if these values have been stable over the past year. NOTE:
  • Patients with suspected Gilbert's syndrome will be considered if bilirubin is grade 2 or better.

Patients with the following prior conditions are excluded:

  • History of pancreatitis within the past 2 years.
  • History of clinically significant nervous system or muscle disease, seizure disorder, AIDS dementia, or psychiatric disorder that would preclude study compliance.
  • History of grade 2 or worse peripheral neuropathy.
  • Intolerance to ddI in previous treated patients.

Prior Medication:

Excluded:

  • More than 4 months total of prior ddI.
  • Any prior ddC, d4T, or 3TC.
  • Prior nonnucleoside reverse transcriptase inhibitors, including L-drugs, nevirapine, TIBO, HEPT, delavirdine, atevirdine, and alpha-APA.
  • Other investigational antiretroviral medications (including foscarnet) or immunomodulators (including all interferons) within 21 days prior to initial study drug dose.
  • Prior prophylactic or therapeutic HIV-1 gp120 or 160 vaccines.
  • Rifampin, rifabutin, astemizole, loratadine, or terfenadine within 21 days prior to initial study drug dose.
  • Any unapproved investigational medication for any indication within 21 days prior to initial study drug dose.

Required:

  • AZT therapy at some time prior to screening. Active substance abuse.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Masking: Double

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pharmacia and Upjohn

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Freimuth WW, Chuang-Stein CJ, Greenwald CA, Cox SR, Edge-Padbury BA, Carberry PA, Wathen LK. Delavirdine (DLV) + didanosine (ddI) combination therapy has sustained surrogate marker response in advanced HIV-1 population. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:163

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted

November 2, 1999

First Submitted That Met QC Criteria

August 30, 2001

First Posted (Estimate)

August 31, 2001

Study Record Updates

Last Update Posted (Estimate)

June 24, 2005

Last Update Submitted That Met QC Criteria

June 23, 2005

Last Verified

November 1, 1996

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 228A
  • M/3331/0017

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV Infections

Clinical Trials on Didanosine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe